Autologous T-cell product expanded ex vivo; provides tumor-reactive lymphocytes that mediate TCR-dependent cytotoxicity as adoptive cell therapy.
Autologous tumor-draining lymph node–derived T cells expanded ex vivo and reinfused to provide tumor-reactive lymphocytes that recognize tumor antigens via native TCRs and kill target cells through perforin/granzyme cytotoxicity and cytokine-mediated immune activation.
Adoptively transferred tumor-reactive T cells recognize the peptide–HLA class I complex via their native TCR and directly kill target cells through perforin/granzyme-mediated cytotoxicity (with possible Fas–FasL and cytokine contributions).
Autologous T-cell product expanded ex vivo; provides tumor-reactive lymphocytes that mediate TCR-dependent cytotoxicity as adoptive cell therapy.
Autologous tumor-draining lymph node–derived T cells expanded ex vivo and reinfused to provide tumor-reactive lymphocytes that recognize tumor antigens via native TCRs and kill target cells through perforin/granzyme cytotoxicity and cytokine-mediated immune activation.
Adoptively transferred tumor-reactive T cells recognize the tumor antigen peptide–HLA-B complex via their native TCR and kill targets via perforin/granzyme cytolysis (and Fas–FasL apoptosis).
Autologous T-cell product expanded ex vivo; provides tumor-reactive lymphocytes that mediate TCR-dependent cytotoxicity as adoptive cell therapy.
Autologous tumor-draining lymph node–derived T cells expanded ex vivo and reinfused to provide tumor-reactive lymphocytes that recognize tumor antigens via native TCRs and kill target cells through perforin/granzyme cytotoxicity and cytokine-mediated immune activation.
Adoptively transferred T cells recognize the tumor peptide–HLA-C complex via native TCRs and kill targets through perforin/granzyme-mediated apoptosis (with possible Fas–FasL/cytokine contributions).
Autologous T-cell product expanded ex vivo; provides tumor-reactive lymphocytes that mediate TCR-dependent cytotoxicity as adoptive cell therapy.
Autologous tumor-draining lymph node–derived T cells expanded ex vivo and reinfused to provide tumor-reactive lymphocytes that recognize tumor antigens via native TCRs and kill target cells through perforin/granzyme cytotoxicity and cytokine-mediated immune activation.
Native TCRs on the infused tumor-reactive T cells recognize the tumor antigen peptide–HLA-DR complex and directly kill the presenting cell via perforin/granzyme and Fas–FasL apoptotic pathways.
Autologous T-cell product expanded ex vivo; provides tumor-reactive lymphocytes that mediate TCR-dependent cytotoxicity as adoptive cell therapy.
Autologous tumor-draining lymph node–derived T cells expanded ex vivo and reinfused to provide tumor-reactive lymphocytes that recognize tumor antigens via native TCRs and kill target cells through perforin/granzyme cytotoxicity and cytokine-mediated immune activation.
Native TCRs on the infused lymphocytes recognize the tumor antigen peptide–HLA-DP complex and directly kill target cells via perforin/granzyme-mediated cytolysis (and related T-cell cytotoxic pathways).